GlassScriptPhysician profile
Jeffrey H Klopper
NPI 1033282017
$18,423.51
in general payments reported to CMS, 2019-2025
36 companies · $3,698 in 2025
The $3,698 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,966 · 2020: $1,052 · 2021: $2,084 · 2022: $2,853 · 2023: $3,923 · 2024: $2,848 · 2025: $3,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,129.19 |
| Education | $339.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,491.57 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,991.63 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,835.09 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,824.87 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,560.14 | 2019-2025 | Ingrezza |
| Abbvie INC. | $1,245.84 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $876.66 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $832.23 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $715.60 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $620.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $501.33 | 2020-2025 | Trintellix |
| Indivior INC. | $498.15 | 2019-2025 | Perseris, Sublocade |
| Lundbeck LLC | $485.97 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $354.07 | 2021-2023 | Qelbree |
| Eisai INC. | $344.37 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $309.22 | 2020-2022 | |
| Corium, LLC | $273.96 | 2022-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $230.08 | 2022-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $215.11 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $179.36 | 2021-2022 | |
| Brainsway USA INC | $164.03 | 2021-2025 | Deep Tms System |
| Luye Pharma (USA) LTD. | $163.16 | 2025 | Erzofri Extended-Release |
| Almatica Pharma LLC | $113.23 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Neuronetics, INC. | $91.83 | 2020 | |
| Bausch Health US, LLC | $85.31 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $57.45 | 2021-2023 | Belsomra |
| Neos Therapeutics, LP | $56.53 | 2022-2024 | Adzenys Xr-Odt |
| Noven Pharmaceuticals, INC. | $56.39 | 2020 | |
| Noven Therapeutics, LLC | $49.42 | 2020-2023 | Secuado |
| Ironshore Pharmaceuticals INC. | $45.81 | 2021-2022 | |
| Tris Pharma INC | $40.84 | 2023 | Dyanavel Xr |
| Amgen INC. | $34.39 | 2022 | |
| Masimo Corporation | $23.23 | 2023 | Emma and Isa |
| Orexo US, INC. | $19.80 | 2019 | |
| Acadia Pharmaceuticals INC | $19.26 | 2025 | Nuplazid |
| Arbor Pharmaceuticals, INC. | $17.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Klopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.